Grufity logoGrufity logo
StocksFundsSearch Filings

BridgeBio Pharma Inc Stock Research

BBIO

13.54USD-0.21(-1.53%)Market Closed

Market Summary

USD13.54-0.21
Market Closed
-1.53%

BBIO Alerts

BBIO Stock Price

BBIO RSI Chart

BBIO Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-4.48

Price/Sales (Trailing)

20.12

Price/Free Cashflow

-5.34

BBIO Price/Sales (Trailing)

BBIO Profitability

Return on Equity

38.98%

Return on Assets

-77.79%

Free Cashflow Yield

-18.74%

BBIO Fundamentals

BBIO Revenue

Revenue (TTM)

107.9M

Revenue Y/Y

-100%

Revenue Q/Q

-100%

BBIO Earnings

Earnings (TTM)

-484.7M

Earnings Y/Y

7.69%

Earnings Q/Q

-0.27%

Price Action

52 Week Range

5.7419.95
(Low)(High)

Last 7 days

-0.9%

Last 30 days

-6.7%

Last 90 days

19.9%

Trailing 12 Months

87.0%

BBIO Financial Health

Current Ratio

4.52

BBIO Investor Care

Shares Dilution (1Y)

8.63%

Diluted EPS (TTM)

-2.84

Peers (Alternatives to BridgeBio Pharma)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
116.8B
26.2B
-8.85% -12.37%
14.75
4.46
-0.48% 38.34%
95.3B
27.0B
-7.15% 22.78%
17.06
3.52
-1.56% 23.65%
49.5B
15.1B
-3.01% -12.71%
10.35
3.29
-33.37% -67.32%
43.1B
10.1B
-1.82% 44.85%
13.78
4.27
-6.61% 115.98%
MID-CAP
8.8B
1.6B
-10.82% -3.21%
137.28
5.5
32.38% -10.36%
4.0B
-
17.83% 16.01%
-10.8
36.9
122.90% -29.67%
2.4B
76.7M
3.87% -11.56%
-7.51
30.96
41.73% -32.75%
2.2B
107.9M
-6.75% 87.02%
-4.48
20.12
54.84% 17.36%
SMALL-CAP
1.5B
119.0M
13.50% 5.58%
-5.31
12.45
-69.61% -584.39%
1.1B
10.0M
10.82% 23.60%
-6.03
105.01
215.65% -47.65%
641.1M
-
-3.13% -86.56%
-0.55
0.32
72.89% 12.32%
487.0M
136.9M
-18.29% -78.97%
-2.07
3.56
116.83% -0.93%
191.0M
241.0M
-22.11% -68.89%
-1.5
0.79
113.96% 27.87%
166.8M
697.0K
51.20% -67.02%
-1.55
239.29
47.98% -35.48%
9.0M
-
-32.41% -88.55%
-0.12
3.21
0.51% -129.47%

Financials for BridgeBio Pharma

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue9.7%10898.0089.0079.0070.00
  S&GA Expenses-13.8%143166181191-
  R&D Expenses-7.3%399431443436-
EBITDA-556----
EBITDA Margin-7.97*----
EBT Margin-7.25*----
Interest Expenses6.4%80.0076.0067.0057.00-
Net Income2.4%-484-496-517-616-586
Net Income Margin11.0%-4.49*-5.04*-7.42*--
Free Cahsflow9.1%-424-466-458-519-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets0.4%626623729862813
  Current Assets0.7%553549642771716
    Cash Equivalents8.1%407377483470372
  Net PPE-6.9%14.0015.0016.0017.0017.00
Liabilities-1.5%1,8391,8681,8591,8771,854
  Current Liabilities-20.4%97.00121119141103
    LT Debt, Non Current1.1%436431434--
Shareholder's Equity2.4%-1,213-1,243-1,041--
  Retained Earnings-7.3%-2,057-1,918-1,780-1,643-1,633
  Additional Paid-In Capital17.9%1,107939917893868
Shares Outstanding6.5%160151149148148
Minority Interest8.6%12.0011.0010.0012.00-0.03
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations3.9%-403-419-460-446-507
  Share Based Compensation-2.4%89.0092.0090.0088.0090.00
Cashflow From Investing-27.9%327453457369220
Cashflow From Financing1145.2%137-13.13306169188
  Buy Backs-0.00----

Risks for BBIO

What is the probability of a big loss on BBIO?

93.7%


Probability that BridgeBio Pharma stock will be more than 20% underwater in next one year

88.9%


Probability that BridgeBio Pharma stock will be more than 30% underwater in next one year.

63.3%


Probability that BridgeBio Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does BBIO drawdown profile look like?

Y-axis is the maximum loss one would have experienced if BridgeBio Pharma was unfortunately bought at previous high price.

Drawdowns

Returns for BBIO

Cumulative Returns on BBIO

-22.7%


3-Year Cumulative Returns

Which funds bought or sold BBIO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-26
ProShare Advisors LLC
reduced
-11.66
182,597
380,610
-%
2023-05-23
Capital Impact Advisors, LLC
reduced
-15.31
209,764
458,702
0.56%
2023-05-22
PUTNAM INVESTMENTS LLC
added
38.41
532,843
797,730
-%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-38.04
160,740
623,740
-%
2023-05-18
JPMORGAN CHASE & CO
reduced
-36.43
1,546,000
5,577,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
reduced
-23.07
371,000
922,000
-%
2023-05-16
PERCEPTIVE ADVISORS LLC
added
12.37
18,687,200
31,618,600
0.93%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
576
8,118,160
8,709,610
-%
2023-05-16
JANE STREET GROUP, LLC
added
196
2,241,080
2,653,000
-%
2023-05-16
Rockefeller Capital Management L.P.
added
8.57
470,000
815,000
-%

1–10 of 28

Latest Funds Activity

Are funds buying BBIO calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own BBIO
No. of Funds

BridgeBio Pharma News

Best Stocks
Short Interest in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Drops ....
Best Stocks,
9 hours ago
Nasdaq
The Associated Press
BridgeBio Pharma: Q1 Earnings Snapshot.
The Associated Press,
27 days ago

Schedule 13G FIlings of BridgeBio Pharma

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
kumar neil
6.42%
9,823,908
SC 13G/A
Feb 09, 2023
vanguard group inc
7.09%
10,591,455
SC 13G/A
Feb 08, 2023
state street corp
5.92%
8,844,943
SC 13G
Feb 01, 2023
blackrock inc.
6.6%
9,834,401
SC 13G/A
Feb 15, 2022
perceptive advisors llc
4.8%
7,128,755
SC 13G/A
Feb 14, 2022
kumar neil
6.05%
9,003,211
SC 13G/A
Feb 09, 2022
vanguard group inc
6.34%
9,331,683
SC 13G/A
Feb 03, 2022
blackrock inc.
6.3%
9,275,590
SC 13G/A
Feb 17, 2021
kkr genetic disorder l.p.
20.9%
31,060,971
SC 13D/A
Feb 16, 2021
american international group, inc.
2.8%
3,381,412
SC 13G/A

BBIO Fair Value

Show Fair-Value

Recent SEC filings of BridgeBio Pharma

View All Filings
Date Filed Form Type Document
May 18, 2023
4
Insider Trading
May 18, 2023
4
Insider Trading
May 18, 2023
4
Insider Trading
May 17, 2023
144
Notice of Insider Sale Intent
May 17, 2023
144
Notice of Insider Sale Intent
May 05, 2023
4
Insider Trading
May 05, 2023
4
Insider Trading
May 04, 2023
10-Q
Quarterly Report
May 04, 2023
S-8
Employee Benefits Plan
May 04, 2023
S-3ASR
S-3ASR

Latest Insider Trading transactions for BBIO

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-17
Kumar Neil
sold
-722,218
14.0095
-51,552
ceo and president
2023-05-17
STEPHENSON BRIAN C
sold
-342,168
14.0095
-24,424
secretary, treasurer & cfo
2023-05-16
HOMCY CHARLES J
acquired
-
-
3,759
-
2023-05-16
Kumar Neil
acquired
-
-
102,249
ceo and president
2023-05-16
STEPHENSON BRIAN C
sold (taxes)
-289,859
14.09
-20,572
secretary, treasurer & cfo
2023-05-16
Kumar Neil
sold (taxes)
-714,321
14.09
-50,697
ceo and president
2023-05-16
STEPHENSON BRIAN C
acquired
-
-
44,996
secretary, treasurer & cfo
2023-05-16
HOMCY CHARLES J
sold (taxes)
-18,317
14.09
-1,300
-
2023-05-03
STEPHENSON BRIAN C
sold
-920,693
14.18
-64,929
secretary, treasurer & cfo
2023-05-03
Kumar Neil
sold
-1,701,740
14.1812
-120,000
ceo and president

1–10 of 50

Neil Kumar
580
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

BBIO Income Statement

2023-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Revenue:  
Total revenue$ 1,826$ 1,694
Operating costs and expenses:  
Cost of license revenue and products sold6511,348
Research and development92,861107,649
Selling, general and administrative31,10843,713
Restructuring, impairment and related charges3,36922,662
Total operating costs and expenses127,989175,372
Loss from operations(126,163)(173,678)
Other income (expense), net:  
Interest income4,153267
Interest expense(20,121)(20,344)
Other expense, net(601)(7,575)
Total other income (expense), net(16,569)(27,652)
Net loss(142,732)(201,330)
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests2,5764,933
Net loss attributable to common stockholders of BridgeBio$ (140,156)$ (196,397)
Net loss per share attributable to common stockholders of BridgeBio, basic$ (0.92)$ (1.35)
Net loss per share attributable to common stockholders of BridgeBio, diluted$ (0.92)$ (1.35)
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic152,645,635145,882,149
Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, diluted152,645,635145,882,149
License and Services Revenue  
Revenue:  
Total revenue$ 1,826$ 235
Product Sales  
Revenue:  
Total revenue $ 1,459

BBIO Balance Sheet

2023-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 407,368$ 376,689[1]
Marketable securities34,12251,580[1]
Investment in equity securities49,80343,653[1]
Receivable from licensing and collaboration agreements10,76117,079[1]
Restricted cash25,50337,930[1]
Prepaid expenses and other current assets25,14521,922[1]
Total current assets552,702548,853[1]
Property and equipment, net13,56614,569[1]
Operating lease right-of-use assets10,53210,678[1]
Intangible assets, net28,11328,712[1]
Other assets20,76720,224[1]
Total assets625,680623,036[1]
Current liabilities:  
Accounts payable4,07611,558[1]
Accrued compensation and benefits18,86931,256[1]
Accrued research and development liabilities37,06439,803[1]
Accrued professional services4,0151,790[1]
Operating lease liabilities, current portion3,6743,675[1]
Deferred revenue, current portion6,6758,156[1]
Other accrued liabilities22,22325,190[1]
Total current liabilities96,596121,428[1]
Term loan, net435,764430,993[1]
Operating lease liabilities, net of current portion11,90412,274[1]
Other long-term liabilities17,50126,643[1]
Total liabilities1,839,2931,867,960[1]
Commitments and contingencies (Note 8)
Redeemable convertible noncontrolling interests(204)(1,589)
Stockholders’ equity (deficit):  
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized;166,626,999 shares issued and 160,435,238 shares outstanding as of March 31, 2023, 156,817,333 shares issued and 150,625,572 shares outstanding as of December 31, 2022167157[1]
Treasury stock, at cost; 6,191,761 shares as of March 31, 2023 and December 31, 2022(275,000)(275,000)[1]
Additional paid-in capital1,106,635938,703[1]
Accumulated other comprehensive loss(12)(328)[1]
Accumulated deficit(2,057,455)(1,918,149)[1]
Total BridgeBio stockholders' deficit(1,225,665)(1,254,617)[1]
Noncontrolling interests12,25611,282[1]
Total stockholders' deficit(1,213,409)(1,243,335)[1],[2]
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit625,680623,036[1]
2029 Notes  
Current liabilities:  
Notes, net735,463734,988[1]
2027 Notes  
Current liabilities:  
Notes, net$ 542,065$ 541,634[1]
[1]The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.
[2]The consolidated balances as of December 31, 2022 and 2021 are derived from the audited consolidated financial statements as of those dates.